| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -77,670 |
| Depreciation and amortization expense | 24,853 |
| Impairment of long-lived assets | 0 |
| Non-cash lease expense, net of tenant improvement allowance | -20 |
| Stock-based compensation expense | 64,459 |
| Change in fair value of contingent considerations and holdbacks | 0 |
| Gain on sale of business | 48,847 |
| Other non-cash adjustments | -2,203 |
| Accounts receivable, net | 22,382 |
| Inventories | 4,229 |
| Prepaid expenses and other current assets | 3,717 |
| Other non-current assets | 1,568 |
| Accounts payable | 9,332 |
| Accrued expenses | 5,751 |
| Accrued compensation | -2,405 |
| Other liabilities | 6,612 |
| Net cash used in operating activities | -47,628 |
| Purchases of property and equipment | 28,004 |
| Purchases of investments | 49,393 |
| Proceeds from maturity of investments | 50,135 |
| Proceeds from sale of business | 2,500 |
| Net cash provided by (used in) investing activities | -24,762 |
| Proceeds from exercise of stock options | 9,343 |
| Proceeds from the issuance of liability related to sale of future revenue | 15,000 |
| Proceeds from issuance under employee stock purchase plan | 4,213 |
| Repurchases of common stock for income tax withholding | 16 |
| Net cash provided by financing activities | 28,540 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | 143 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -43,707 |
| Cash and cash equivalents at beginning of period | 229,132 |
| Cash and cash equivalents at end of period | 185,425 |
Twist Bioscience Corp (TWST)
Twist Bioscience Corp (TWST)